Welcome to AMYPAD!
We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.
The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aimed to:
- improve the diagnostic work-up of people suspected to have Alzheimer’s disease and their management
- understand the natural history of the disease in a pre-symptomatic stage
- select people for treatment trials aiming at preventing Alzheimer’s disease
💡 You can now make a formal request to access our data!
|
|
|
Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD at EANM2023
19 Sep 2023
Springer Healthcare IME hosted a symposium entitled "Preparing for the new era of neuroimaging for Alzheimer’s disease"......
Revealing an earlier and more effective way to diagnose Alzheimer’s disease
07 Sep 2023
The Innovative Health Initiative featured the recent AMYPAD article on their website.....
Welcome to the 24th issue of the AMYPAD Newsletter
31 Jul 2023
Such exciting times for our project! Just before the summer there has been a surge in activity showing that AMYPAD is more alive then ever, despite the end of the IMI funding period....
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.
